FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or S	ection 30(h) of the In	vestment Con	npany Act of 1940						
1. Name and Address of Reporting Person*				uer Name and Ticker 1Abs Therapeu			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Gad Thomas	<u>6</u>			<u>in 100 i merapea</u>	<u>,</u>	[X	Director	10% 0	Dwner		
(Last) (First) (Middle)				te of Earliest Transac 4/2021	tion (Month/D	ay/Year)	- x	Officer (give title below)	below	(specify)		
C/O Y-MABS THERAPEUTICS, INC.				4/2021			See remarks					
230 PARK AVE	ENUE SUITE	3350										
(Street)				mendment, Date of (Driginal Filed	(Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
NEW YORK	NY	10169					X	Form filed by On	e Reporting Pers	on		
,								Form filed by Mo Person	re than One Rep	orting		
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
Date		2. Transaction Date (Month/Day/Yea		Execution Date, Transaction Disposed Of (D)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			

 (Month/Day/Year)
 8)
 Owned Following
 (I) (Instr. 4)
 Owned Following

 Code
 V
 Amount
 (A) or (D)
 Price
 For and 40
 (I) (Instr. 4)
 Owned Following

> Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(0.9.) parts, canno, control and coordinate)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Employee Stock Option (right to buy) ⁽¹⁾	\$15.73	12/14/2021		A		110,000		(2)	12/14/2031	Common stock	110,000	\$0	110,000	D	

Explanation of Responses:

1. Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.

2. The stock option shall vest and become exercisable as to 25% of the shares subject to the option on December 14, 2022, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Remarks:

Chairman, President and Head of Business Development & Strategy

/s/ Thomas Gad

<u>12/15/2021</u> Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.